RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BiondVax Pharmaceuticals Stock

BiondVax Pharmaceuticals ROCE 2024

BiondVax Pharmaceuticals ROCE

-1.56

Ticker

BVXV

ISIN

US09073Q1058

WKN

A14TFZ

In 2024, BiondVax Pharmaceuticals's return on capital employed (ROCE) was -1.56, a 0% increase from the 0 ROCE in the previous year.

BiondVax Pharmaceuticals Aktienanalyse

What does BiondVax Pharmaceuticals do?

BiondVax Pharmaceuticals Ltd is an Israeli biopharmaceutical company specializing in the development and production of vaccines. The company was founded in 2003 and has since developed an innovative approach to preparing influenza vaccines. BiondVax's business model is focused on meeting the growing demand for vaccines while ensuring better efficacy and safety. The company uses the latest technologies and research methods to carefully examine the properties of viruses and develop tailor-made vaccines based on that information. BiondVax offers a wide range of products that focus on protecting against influenza viruses. The company's most important product is the M-001 vaccine, which has broad efficacy against various types of influenza viruses. This vaccine differs from conventional vaccines by independently stimulating and enhancing immunity, resulting in longer-lasting protection. The company is also developing other vaccines aimed at protecting against other infectious diseases such as herpes simplex or AIDS. A unique feature of BiondVax is the use of a targeted approach to cancer treatment, where the patient's immune system is specifically activated to kill cancer cells. BiondVax is a dynamic company that continuously invests in improving its technology and products. Since its founding, the company has made significant progress and achieved a number of milestones. For example, in 2017, the company received an important approval from the US Food and Drug Administration, allowing it to conduct a clinical trial process for its vaccine. BiondVax has also formed partnerships with other leading companies in the healthcare industry to support its research and development. Collaborating with companies such as Merck, Novartis, or the US Department of Defense allows BiondVax to further expand its business and develop more effective vaccines. Over the years, BiondVax has introduced numerous innovations in the industry. For example, the company has specialized in designing peptides, which are proteins that can serve as the basis for vaccines. The company has also utilized the latest technologies in immunology to make its vaccines even safer and more effective. Overall, BiondVax Pharmaceuticals Ltd has made impressive progress in recent years and has established itself as a leading company in the field of vaccine development. Through its innovative technologies and targeted approach to disease prevention, BiondVax is able to significantly impact the healthcare industry and serve a wider range of patients than before. BiondVax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling BiondVax Pharmaceuticals's Return on Capital Employed (ROCE)

BiondVax Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing BiondVax Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

BiondVax Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in BiondVax Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about BiondVax Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of BiondVax Pharmaceuticals this year?

The ROCE of BiondVax Pharmaceuticals is -1.56 undefined this year.

How has the ROCE (Return on Capital Employed) of BiondVax Pharmaceuticals developed compared to the previous year?

The ROCE of BiondVax Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of BiondVax Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that BiondVax Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of BiondVax Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that BiondVax Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from BiondVax Pharmaceuticals impact the company?

An increase in the ROCE of BiondVax Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of BiondVax Pharmaceuticals affect the company?

A decrease in ROCE of BiondVax Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of BiondVax Pharmaceuticals?

Some factors that can affect BiondVax Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of BiondVax Pharmaceuticals so important for investors?

The ROCE of BiondVax Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can BiondVax Pharmaceuticals take to improve the ROCE?

To improve the ROCE, BiondVax Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does BiondVax Pharmaceuticals pay?

Over the past 12 months, BiondVax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BiondVax Pharmaceuticals is expected to pay a dividend of 0 ILS.

What is the dividend yield of BiondVax Pharmaceuticals?

The current dividend yield of BiondVax Pharmaceuticals is .

When does BiondVax Pharmaceuticals pay dividends?

BiondVax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of BiondVax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is BiondVax Pharmaceuticals located?

BiondVax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von BiondVax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BiondVax Pharmaceuticals from 9/30/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did BiondVax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of BiondVax Pharmaceuticals in the year 2023?

In the year 2023, BiondVax Pharmaceuticals distributed 0 ILS as dividends.

In which currency does BiondVax Pharmaceuticals pay out the dividend?

The dividends of BiondVax Pharmaceuticals are distributed in ILS.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BiondVax Pharmaceuticals

Our stock analysis for BiondVax Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BiondVax Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.